Previously, HCCI analyzed Ozempic medication use in the ESI population and found that the percentage of patients using Ozempic that had a diabetes diagnosis, the condition Ozempic is clinically indicated to treat, had decreased from 92% in 2018 to 77% 2021. This indicated a growing trend of off-label use of Ozempic. Our findings aligned with reports at the time of off-label use of Ozempic for weig...
Colorectal cancer is the fourth most commonly diagnosed cancer in the U.S. and the second leading cause of cancer death. Recently, a growing number of young people have been diagnosed with colorectal cancer. According to the American College of Surgeons, the incidence rate of early onset colorectal cancer is expected to double by 2030. While these statistics are alarming, colon and rectal cancer a...
Prior HCCI research has shown that women are more likely to use health care services than men. Among people who receive health insurance through their employer, we find that women are, on average, 1.4 times more likely to receive any health care services than men, and this trend has remained consistent over time. As shown in Figure 1, utilization differences vary slightly by service categories. Wo...
The Health Care Cost Institute (HCCI), in collaboration with West Health, conducted an analysis on the use of telehealth mental health services among people with employer-sponsored insurance (ESI). We found that telehealth played an outsized role in the delivery of mental health services starting in 2020, with over 40% of mental health visits occurring via telehealth from 2020-2022. Fema...
The International Federation of Health Plans (iFHP) has published its 2024 International Healthcare Cost Comparison Report, marking its latest biennial analysis of global healthcare costs. Compiled in collaboration with the Health Care Cost Institute (HCCI), the report compares costs for inpatient and outpatient treatments, as well as prescription drugs, across nine countries using data from 2022....
